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ABSTRACT 
 
Aims: Retinoblastoma is a childhood ocular tumor rapidly developing from the immature cells of 
the retina due to loss of functional retinoblastoma protein. Digoxin, a cardiac glycoside, has been 
reported to be effective in inducing apoptosis, cell cycle arrest, and cytotoxic effects on human 
cancers. In this regard, the present study aims to investigate whether digoxin could suppress 
retinoblastoma cancer through the regulation of transforming growth factor-β (TGF-β) signaling 
pathway.  
Methodology: The effects of digoxin on Y-79 cells, retinoblastoma cancer cell line, were 
investigated using MTT (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazoli-umbromide) and BrdU 
(bromodeoxyuridine) assays to measure cellular cytotoxicity effects and cell apoptosis, 
respectively. Also, a qPCR assay was employed to analyze the mRNA expression levels of TGFβ 
signaling pathway including C-MYC, P21, P15, TGFβRI, TGFβRII, and SMAD2, 3, and 4 genes.  
Results: The results of the cell function assays revealed that digoxin inhibited the cell viability and 
proliferation of Y-79 cells. In addition, it was found that digoxin significantly suppressed C-MYC 
expression and enhanced the expression of P21, P15, SMAD2 and SMAD4 genes in a dose-and 
time-dependent manner. However, the obtained results could not detect any significant effect of 
digoxin on TGFβRI, TGFβRII and SMAD3 genes.  
Conclusion: Taken together, the findings of the present study suggest that digoxin could be a 
potential therapeutic agent in the treatment of retinoblastoma by regulating the cell cycle genes via 
a non-canonical TGF-β signaling pathway. 
 
 
Keywords: c-Myc; eye cancer; gene expression; P21; P15; real-time PCR. 
 
1. INTRODUCTION 
 
Retinoblastoma (Rb) is a rare form of eye cancer 
that originates from the immature cells of a 
retina. This intraocular malignancy is the most 
common childhood eye cancer. There are two 
forms of this cancer; bilateral (15% inheritable) 
and unilateral (85% non-heritable). In spite of the 
fact that this disease may occur as part of a 
familial cancer syndrome, the majority of 
retinoblastoma cases arise with no preceding 
family history [1]. Retinoblastoma is the first 
human malignancy that has been confirmed to 
have a nature of genetic origin [1,2]. The loss of 
Rb protein functions, owing to genetic alterations, 
has been accepted as a genetic factor for human 
cancer, particularly retinal cell malformation. 
However, recent studies suggested that 
amplification of the MYCN oncogene might 
initiate retinoblastoma in the presence of non-
mutated Rb gene [3-7]. 
 
To date, major treatment strategies for 
retinoblastoma involve enucleation, external 
beam radiation therapy (RT), radioactive plaques 
(I-125 brachytherapy), cryotherapy, laser 
photoablation and chemotherapy [8-10]. 
Although these therapies have improved the 
survival rate of the cancer (up to 98%), 
chemotherapeutic resistance remains a 
significant hurdle in the treatment of 
retinoblastoma [11,12]. 
Cardiac glycosides (CGs) including digoxin, 
ouabain, bufalin and digitoxin have been purified 
from foxglove and have a long history used in the 
treatment of congestive heart failure and 
arrhythmia [13,14]. The effect of digoxin is 
mediated by the inhibition of the plasma 
membrane Na+ K+-ATPase (sodium-potassium 
adenosine triphosphatase), ion pump and 
stimulation of Ca2+ influx [15,16]. Also, it has 
been suggested that digoxin exerts anti-
proliferative and apoptotic effects against 
malignant cells in vitro and animal models                
[17-22]. 
 
Retinoblastoma like other types of cancer may 
be stratified into various biological subgroups 
based on their global gene expression profiles 
[10]. These subgroups vary in their genetic 
changes and may respond differently to 
anticancer agents. Given that the anticancer 
effects and molecular mechanisms of digoxin in 
retinoblastoma cancer cells are unknown, the 
present study aimed at evaluating the effects of 
digoxin on cellular function and mRNA 
expression of TGFβ target genes in Y-79, a 
retinoblastoma cell line. 
 
2. MATERIALS AND METHODS 
 
2.1 Cell Culture 
 
The human retinoblastoma Y-79 cell line was 
obtained from National Cell Bank of Iran (NCBI) 
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affiliated to Pasteur Institute (Tehran, Iran). The 
cells were grown in suspension at a 
concentration of 105-106 cells/ml in RPMI-1640 
medium (Gibco; Germany) containing 10% fetal 
bovine serum (FBS) (Gibco; Germany), 2 mM L-
glutamine, 1 mM sodium pyruvate, and 
antibiotics (100 U/ml of penicillin and 100 µg/ml 
of streptomycin). Cell culture condition designed 
at 37°C in a humidified atmosphere of 5% CO2-
95% air. 
 
2.2 Digoxin Treatment 
 
The treatment of cells with digoxin (Sigma-
Aldrich, Belgium) was conducted as previously 
described [23]. Briefly, digoxin was dissolved by 
dimethylsulfoxide (DMSO) with a concentration 
of 10 µM and stored at -20°C. The Y-79 cells in 
each experiment were treated using a different 
range of digoxin concentrations (as explain in the 
below sections). The concentration of DMSO 
was equal in all conditions with the exception of 
the untreated group. 
 
2.3 MTT Assay 
 
The cytotoxicity effect of digoxin was measured 
by the MTT assay as previously described               
[22,24]. Briefly, Y-79 cells were seeded in 96-well 
flat-bottom microtitration plates (SPL Life 
Sciences; South Korea) at a density of 4×104 
cells/well (200 µl media/well). After reaching to 
~85% confluence, the cells were treated with 
various concentrations of digoxin (0.0, 0.5, 1, 2 
and 3 µM). In all in vitro experiments, control 
cells were incubated with dimethylsulfoxide 
(DMSO) alone (with a final concentration 0.2%).  
 
2.4 BrdU Assay 
 
The BrdU assay was performed using BrdU 
ELISA kit as previously described [24]. Briefly, 
the Y-79 cells were seeded in 96-well flat-bottom 
microtitration plates at a density of 4×104 
cells/well (100 µl media/well). Then, the cells 
were treated with digoxin (0.0, 0.5, 1, 2 and 3 
µM) and the cell apoptosis calculated as 
previously described [24]. 
 
2.5 RNA Isolation and cDNA Synthesis 
 
To extract RNA from cells under study, the 
TriPure Isolation Reagent (Roche) was used. 
After treatment of Y-79 cells with digoxin followed 
time 24, 48 and 72 hours, RNA was extracted 
from cells and quantity spectrophotometric assay 
was done using the ND-1000 Nanodrop. The 
reverse transcription reaction was completed 
(Revert Aid First Strand cDNA Synthesis Kit, 
Takara BIO) as previously described [25,26]. 
Total RNA was transcribed to cDNA in a reverse 
transcription reaction. In brief, 1 µ total RNA with 
2 µl dNTPs, 1 µl oligo dT, 1 µl RTase M- MULV 
(200 U / µl ), 1 µl RNase inhibitor (20 U / µl ) and 
4 µl  reaction buffer 5X. The synthesized cDNA 
was stored at -20°C until use.  
 
2.6 Real-Time PCR Test 
 
Real- time PCR test was performed to analyze 
the expression level of genes in the treated and 
non-treated cells as described previously (25]. 
Briefly, Real-time PCR reaction in a volume of 20 
µl including 10 µl of SYBR Premix Ex Taq II 
(Takara Bio), 4 µl of the product cDNA, 1µl of 
each primer (10 pmol) and 4 µl nuclease-free 
water was completed. Temperature conditions 
consisted of an initial activation step at 95°C for 
30 seconds, followed by 40 cycles of 
denaturation (10 seconds at 95°C), annealing 
(30 seconds at 60°C) and extension (45 seconds 
at 72°C). To evaluate the specificity of the 
amplified products, the melting curve of a 
temperature of 55 to 95 degrees was evaluated. 
The sequences of specific primers for studied 
genes are listed in Table 1. Quantitative gene 
expression data were normalized to the 
expression levels of control/housekeeping gene, 
GAPDH. 
 
2.7 Statistical Analysis 
 
Statistical analysis for multiple comparisons of 
differences between treatment groups was 
performed with SPSS software. Data analysis for 
gene expression was performed by 2-∆∆ct method. 
The standard error of means was computed and 
analysis of variance (ANOVA, Tukey’spost tests) 
completed via GraphPad Prism 5.0 software.              
P values less than 0.05 were considered to 
indicate statistically significant differences 
between data sets. 
 
3. RESULTS AND DISCUSSION 
 
3.1 Digoxin Induces the Apoptosis as   
well as Decreases Growth and 
Proliferation of Y-79 Cells 
 
To determine the inhibitory effect of digoxin on 
cell proliferation in Y-79, the present study 
analyzed the cell growth by performing MTT 
assay with various conditions. The data 
generated from the present study clearly showed 
that digoxin treatment significantly reduces the 
viability of Y-79 cells in a dose- and time-
dependent manner (Table 2). Fig. 1 shows the 
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cell response to different drug concentrations 
(0.0, 0.5, 1, 2 and 3 µM) for a time course of 24, 
48 and 72 h. The results of cell function assays 
revealed a significant change in the cell viability 
in the treated versus untreated Y-79 cells 
(P<0.05) at 48h and 72h. 
 
Moreover, to examine whether cardiac 
glycosides can promote apoptosis in Y-79 cells, 
the researchers analyzed apoptotic index using a 
BrdU experiment in the digoxin treated cells 
compared to controls (Fig. 2). The apoptotic 
findings revealed a significant change in the cell 
death in the treated versus control cells (P<0.05) 
at 48h and 72h. 
 
The obtained results showed that the cytotoxicity 
and apoptosis effects of digoxin on 
retinoblastoma cell line are time-and dose-
dependent (Table 2). Interestingly, the findings of 
the present study revealed that the cytotoxic 
effect of the digoxin is not considerable after 24 h 
incubation regardless of the concentration in the 
cell line. Besides, its apoptotic effect like its 
toxicity seems to be a time-and dose-dependent 
manner. 
 
3.2 Digoxin Regulates mRNA Expression 
of TGFβ Signaling Related Genes, 
p21, p15 and c-Myc 
 
To study the ability of the digoxin as an 
anticancer agent at the molecular level, we 
evaluated its effects on mRNA expression of 
TGFβ signaling-related genes including cyclin 
dependent kinase inhibitors (CDKI), p21, p15 
and c-Myc genes which are involved in cell cycle 
progression. As Fig. 3 shows, digoxin could up-
regulate p15 and p21 (P<0.05) while down-
regulating c-Myc (P<0.05) at the mRNA 
expression level in retinoblastoma cells. 
 
It is now well established that members                      
of the cardiac glycosides including digoxin, 
bufalin and ouabain are currently used in the 
treatment of congestive heart failure and 
arrhythmia. Also, digoxin has been                       
suggested to possess anticancer activity in some 
human cancer cells by the inhibition of cell cycle 
process [27-33]. The cell function assays 
conducted in this study revealed that digoxin 
significantly reduced the cell viability and induced 
apoptosis in Y-79 cells. The digoxin had the 
highest time- and dose-dependent cytotoxicity 
and apoptosis on the cells. As the results 
indicated, the effect is more significant after 48 h 
incubation regardless of the concentration. The 
potent toxic activity of digoxin and more than 
2600 drugs in retinoblastoma cells has already 
been reported in previous studies [23]. 
Accordingly, the ranges of the treatment 
conditions in this study were designed around 
the reported IC50. 
 
To further examine the ability of the digoxin as an 
anticancer drug, here, we evaluated its effects on 
mRNA expression of the genes involved in cell 
cycle progression in retinoblastoma cells. The 
findings revealed the capability of digoxin in the 
up-regulation of p21 and p15, tumor suppressor 
genes, and down-regulation of c-Myc mRNA 
expression in retinoblastoma cells. Interestingly, 
regulation of these genes was detected as part of 
TGFβ signaling pathway by digoxin treatment but 
not on the other related genes, TGFβRI, 
TGFβRII and SMAD3. 
 
Research efforts in the last decade have 
postulated various mechanisms to explain the 
digoxin-mediated control of tumor cell 
proliferation. However, the exact mechanism of 
the anti-tumor activity of digoxin remains unclear. 
Previous studies suggested that cardiac 
glycosides bind to Na+, K +-ATPase pump, 
which in turn triggers a complex cellular signaling 
cascade that results in the activation of MAPKs 
(mitogen-activated protein kinases). 
Subsequently, the activation of MAPKs could 
lead to increased expression of the cell cycle 
inhibitor of p21 [34].  
 
Table 1. The specific primers used for studied genes 
 
Gene name Forward & reverse primers sequences Product size (bp) 
P15 FW: 5 '- AGGTGGACCTGGAGACTCTCAG -3' 205 
RV: 5 '- TCCTCTTGGAGAAGATCAGCCG -3' 
P21 
 
FW: 5 '- ACGGAGTCAACCGTTTCGGGAG -3' 218 
RV: 5 '- GGTCGGGTGAGAGTGGCAGG -3' 
c-Myc FW: 5 ' - AAGGTCAGAGTCTGGATCAC-3' 140 
RV: 5 ' -TAACTACCTTGGGGGCCTTT-3' 
GAPDH FW: 5’- CACCAGGGCTGCTTTTAAC-3’ 190 
RV: 5’-ATCTCGCTCCTGGAAGAT-3’ 
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Table 2. Data resulted from cell function assays 
 
MTT assay 24h 48h 72h 
Concentrations 
of digoxin(µM) 
OD value 
(mean±SEM) 
P value Inhibition 
rate(IR)% 
OD value 
(mean±SEM) 
P value Inhibition 
rate(IR)% 
OD value 
(mean± SEM) 
P value Inhibition 
rate(IR)% 
Untreated 
Control 
0.5 
1 
2 
3 
0.053±0.004 
0.051±0.003 
0.050±0.002 
0.047±0.001 
0.044±0.002 
0.043±0.001 
 
0.958 
0.832 
0.590 
0.326 
0.247 
 
3.77 
4.86 
11.32 
16.98 
18.86 
0.059±0.002 
0.056±0.002 
0.56±0.001 
0.52±0.001 
0.048±0.001 
0.045±0.001 
 
0.854 
0.643 
0.194 
0.020 
0.005 
 
5.08 
6.34 
11.86 
18.64 
23.72 
0.074±0.002 
0.068±0.006 
0.066±0.004 
0.057±0.003 
0.052±0.004 
0.050±0.002 
 
0.788 
0.601 
0.037 
0.016 
0.005 
 
8.10 
10.01 
22.97 
29.72 
32.43 
BrdU assay 24h 48h 72h 
Concentrations 
of digoxin (µM) 
OD value 
(mean±SEM) 
P value Inhibition 
rate(IR)% 
OD value 
(mean±SEM) 
P value Inhibition 
rate(IR)% 
OD value 
(mean±SEM) 
P value Inhibition 
rate(IR)% 
Untreated 
Control 
0.5 
1 
2 
3 
0.092±0.003 
0.088±0.003 
0.087±0.002 
0.084±0.002 
0.081±0.001 
0.080±0.003 
 
0.937 
0.78 
0.417 
0.259 
0.137 
 
4.34 
5.01 
8.69 
11.95 
13.04 
0.114±0.001 
0.108±0.003 
0.106±0.002 
0.098±0.004 
0.091±0.003 
0.084±0.004 
 
0.850 
0.76 
0.136 
0.031 
0.013 
 
5.26 
6.43 
14.03 
20.17 
26.31 
0.124±0.003 
0.117±0.002 
0.116±0.002 
0.097±0.005 
0.092±0.005 
0.088±0.002 
 
0.732 
0.0654 
0.027 
0.012 
0.007 
 
5.64 
9.43 
21.77 
25.80 
29.03 
  
 
 
Sheikhzade et al.; BJMMR, 15(6): 1-10, 2016; Article no.BJMMR.25709 
 
 
 
6 
 
 
 
Fig. 1. Effect of digoxin on the cell viability of the Y-79 cells 
Y-79 cells were treated by 0.0, 0.5, 1, 2 and 3 µM for different time courses. The cell toxicity was examined by 
MTT assay as described in methods. All data are reported as the percentage change in comparison with the 
controls. Analysis of one-way ANOVA was used to compare the cell viability of Y-79 cells in different 
concentrations of digoxin compared to controls. Results are expressed as the mean±SEM from three 
independent experiments. P value < 0.05 was regarded as statistically significant 
 
 
 
Fig. 2. Impact of digoxin on retinoblastoma cell proliferation 
The Y-79 cells were treated by 0.0, 0.5, 1, 2 and 3 µM for different time. Cell apoptosis was examined by BrdU 
assay as described in methods. Analysis of one-way ANOVA was used to compare the cell apoptosis of Y-79 
cells in different concentrations of digoxin to control. Results are expressed as the mean±SEM from three 
independent experiments. P value < 0.05 was regarded as statistically significant 
 
Various studies demonstrated that p21 could be 
regulated by multiple approaches and factors 
such as TGFβ, p53-dependent and p53-
idependent manners [35-37]. There are typically 
several transcription-binding sites in the 
regulatory region of p21such as p53, STAT3, 
Sp1, Stat1 and SREBP [38-40]. Also, other 
molecular mechanisms and signaling pathways 
such as activations of PI3K/Akt MAPKs and 
ERK1/2 pathways could regulate the p21 gene 
expression [34,41-43]. Kumar and colleagues 
demonstrated an up-regulation of p21 via 
PI3K/Akt pathway in digoxin-treated human 
glioma cell lines (LN-18 and LN-229 cells [41]. 
Kometiani reported that digitoxin concentration 
close to or at the plasma level regulates p21 
gene expression in breast cancer cell line [34]. 
The most recent study showed the effects of 
digoxin on lung cancer cells via inhibiting multiple 
src-related signaling pathways [22]. The findings 
of the present study, in agreement with previous 
studies, revealed the up-regulation of p21 in the 
retinoblastoma treated with digoxin compared to 
controls. 
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Fig  3. Impact of digoxin on P21, P15 and c-Myc gene expression in retinoblastoma 
Digoxin treatment significantly regulated the expression of studied genes 
 
Additionally, we analyzed the expression of other 
TGFβ signaling related genes including p15, c-
Myc, TGFβRI, TGFβRII and SMAD2, 3, 4 genes 
with different digoxin concentrations (0.0, 0.5, 1, 
2 and 3 µM) at three different incubation time 
(0.0, 24h, 48h and 72h). Interestingly, in addition 
to p21, there were significant up-regulation and 
down-regulation of p15 and c-Myc genes, 
respectively. However, we could not observe any 
significant changes in the mRNA expression of 
other TGFβ related genes including TGFβRI, 
TGFβRII and SMAD3. In consistent with the 
results of the present study, different studies 
have indicated that the downstream of TGFβ 
signaling genes could be regulated by SMAD-
independent manner [44-46]. 
 
The results obtained from this study raise a 
critical question: How could digoxin regulate 
above genes without the contribution of other 
TGFβ signaling compartments. With respect to 
the findings, there are several possibilities 
including: (1) drug-mediated targeted disruption 
of multiple protein activities through functional 
inhibition of the vital genes, (2) association of the 
TGFβRI, TGFβRII and SMAD3 mRNA 
expression with different miRNAs and/or long 
non-coding RNAs (lncRNAs), (3) the modulation 
of these genes under different histone 
modifications such as acetylation, methylation, 
ubiquitinilation, or (4) epigenetic (e.g., 
methylations) and genetic factors such as gene-
gene and gene-environment interactions. Further 
studies are clearly required to determine whether 
digoxin acts as an anticancer in retinoblastoma 
via inhibiting Myc proto-oncogene and activating 
p21 and p15, cell cycle inhibitors. 
 
4. CONCLUSION 
 
In conclusion, it was shown that digoxin was able 
to reduce cell proliferation and induce apoptosis 
in a dose and time-dependent manner in 
retinoblastoma. Moreover, as far as the authors 
are concerned, the results of the present study, 
for the first time, indicated that this 
chemotherapeutic agent could act via a non-
canonical TGFβ signaling pathway in 
retinoblastoma. 
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